2011 – now

394. "Novvel peptide-based compounds for use in the prevention, treatment and/or detection of cancer"
Edgar Schmitt, Horst Kunz, Natascha Stergiou, Nikola Gaidzik,  PCT Int. Appl. (2019), WO 2019179923 A1 20190926. Eur. Pat. Appl. (2019), EP 3542814 A1 20190925.

393."Immunisation with a synthetic vaccine consisting of a tumour-associated MUC1-glycopeptide conjugated to Tetanus Toxoid significantly reduced breast tumour growth"
Natascha Stergiou, Nikola Gaidzik, Anne-Sophie Heimes, Sarah Dietzen, Pol Besenius, Jörg Jäkel, Walburgis Brenner, Marcus Schmidt, Horst Kunz*, Edgar Schmitt*, Cancer Immunol. Res. 2019, 7, 113-122; DOI: 10.1158/2326-6066.cir-18-0256.

392. "Synthetic MUC1 antitumor vaccine with incorporated 2,3-sialyl-T carbohydrate antigen inducing a significant immune response with isotype specificity"
David Straßburger, Markus Glaffig, Natascha Stergiou, Sabrina Bialas, Pol Besenius, Edgar Schmitt, Horst Kunz, ChemBioChem 2018, 19, 1142-1146, DOI: 10.1002/cbic.201800148. doi.org/10.1002/cbic.201800148

391. "A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells"
Markus Glaffig, Natascha Stergiou, Sebastian, Hartmann, Edgar Schmitt, Horst Kunz, ChemMedChem 2018, 13, 25-29, DOI: 10.1002/cmdc.201700646. doi.org/10.1002/cmdc.201700646

390. "Carbohydrates as Stereodifferentiating Auxiliaries"
H. Kunz, A. Stoye,  in Topics in Heterocyclic Chemistry, Vol. “Heterocycles as Chiral Auxiliaries in Asymmetric Synthesis” (Ed. M. Braun), Chapter 7, Springer Berlin, Heidelberg, 2017, doi.org/10.1007/7081_2017_7; in press.

389. "Synthetic Antitumor Vaccines through Coupling of Mucin Glycopeptide Antigens to Proteins"
M. Glaffig, H. Kunz, in “Coupling and Decoupling of Diverse Molecular Units in Glycosciences”, Chapter 2, (Eds. Z. Witczak, R. Bielski), Springer International Publishing AG, Cham, 2018, p. 37 - 65.

388. "Immunization with a synthetic human MUC1 glycopeptide vaccine against tumor-associated MUC1 breaks tolerance in human MUC1 transgenic mice"
N. Stergiou, M. Glaffig, H. Jonuleit. E. Schmitt, H. Kunz, ChemMedChem 2017, 12, 1424-1428.  DOI: 10.1002/cmdc.201700387.

387. "Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant"
M. Glaffig, N. Stergiou, E.Schmitt, H. Kunz, ChemMedChem 2017, 12, 722-727.  DOI: 10.1002/cmdc.201700254.

386. "Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures"
C. Pett, Hui Cai, Jia Liu, B. Palitzsch, M. Schorlemer, S. Hartmann, N. Stergiou, Mengji Lu, H. Kunz, E. Schmitt, U. Westerlind, Chem. Eur.J. 2017, 23, 3875-3884, DOI:10.1002/chem.201603921.

385. "Polymeric Selectin Ligands Mimicking Complex Carbohydrates: From Selectin Binders to Modifiers of Macrophage Migration"
K. E. Moog, M. Barz, M. Bartneck, F. Beceren-Braun, N. Mohr, Z. Wu, L.; Braun, J. Dernedde, E. A. Liehn, F. Tacke, T. Lammers, H. Kunz, R. Zentel, Angew. Chem. 2017, 129, 1438-1443; Angew. Chem. Int. Ed. 2017, 56, 1416-1421.

384. "Protein kinase CK2 governs the molecular decision between encephalitogenic Th17 cell and Treg cell development"
A. Ulges, E. J. Witsch, G. Pramanik, M. Klein, K. Birkner, U. Bühler, B. Wasser, F. Luessi, N. Stewrgiou, S. Dietzen, T.-J. Brühl, T. Bohn, G. Bündgen, H. Kunz, A. Waisman, H. Schild, E. Schmitt, F. Zipp, T. Bopp, Proc. Natl. Acad. Sci. USA 2016, 113, 10145-10150.

383. „Synthetic MUC1 Antitumor Glycopeptide Vaccines with Varied Glycosylation Pattern Bearing R/S Configured Pam3CysSerLys4
Lei Shi, Hui Cai, Zhi-Hua Huang, Zhan-yi Sun, Yong-Xiang Chen, Yu-Fen Zhao, H. Kunz, Yan-Mei Li, ChemBioChem 2016, 17, 1412-1417.

382. “Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein”
Hui Cai, F. Degliangeli, B. Palitzsch, B. Gerlitzki, H. Kunz, E. Schmitt, R. Fiammengo, U. Westerlind, Bioorg. Med. Chem. 2016, 24, 1132-1135; doi:10.1016/j.bmc.2016.01.044

381. “A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer”  B. Palitzsch, N. Gaidzik, N. Stergiou, S. Stahn, S. Hartmann, B. Gerlitzki, N. Teusch, P. Flemming, E. Schmitt, H. Kunz, Angew. Chem. 2016, 126, 2944-2949; Angew. Chem. Int. Ed. 2016, 55, 2894-2898; DOI: 10.1002/anie.201509935.

380. “Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers”
M. Glaffig, B. Palitzsch, N. Stergiou, C. Schüll, D. Straßburger, E. Schmitt, H. Frey, H. Kunz, Org. Biomol. Chem. 2015, 13, 10150-10154; DOI: 10.1039/C5OB01255D

379. “Fluorenylmethoxycarbonyl-Protected O-Glycosyl-N-methyl Amino Acids: Building Blocks for the Synthesis of Conformationally Tuned Glycopeptide Antigens”
A. Buba, H. Löwe, H. Kunz, Eur. J. Org. Chem2015, 26, 5764-5774. DOI: 10.1002/ejoc.201500929

378."Stereoselective Total Synthesis of the Diastereomeric Tricyclic Alkaloids Tetraponerine-7 and -8 Using O-Pivaloylated D-Arabinopyranosylamine as the Common Auxiliary"
I. Straßnig, K. Körber, U. Hünger, H. Kunz, Synthesis 2015, 47, 2299-2316.

377. Review “Mucin Glycopeptide-Protein Conjugates – Promising Antitumor Vaccine Candidates”
B. Palitzsch, M. Glaffig, H. Kunz, Isr. J. Chem. 2015, 55, 256-267; DOI: 10.1002/ijch.201400131

376. “Antibody induction directed against the tumor-associated MUC4 glycoprotein”
H. Cai, B. Palitzsch, S. Hartmann, N. Stergiou, H. Kunz, E. Schmitt, U. Westerlind, ChemBioChem. 2015, 16, 959-967; DOI: 10.1002/cbic.201402689

375. "A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes“
B. Palitzsch, S. Hartmann, N. Stergiou, M. Glaffig, E. Schmitt and H. Kunz, Angew. Chem. 2014, 126, 14469-14473; Angew. Chem. Int. Ed. 2014, 51, 14245-14249; DOI:10.1002/anie.201406843 

374. "CpG-loaded multifunctional cationic Nanohydrogel particles as self-adjuvanting glycopeptide antitumor Vaccines“
S. Hartmann, L. Nuhn, B. Palitzsch, M. Glaffig, N. Stergiou, B. Gerlitzki, E. Schmitt, H. Kunz, R. Zentel, Adv. Healthcare Mater. 2015, 4, 522-527, DOI: 10.1002/adhm.201400460

373. "Tumour‐associated glycopeptide antigens and their modification in anticancer vaccines“
S. Hartmann, B. Palitzsch, M. Glaffig, H. Kunz, Specialist Periodical Report, Carbohydrate Chemistry: Chemical and Biological Approaches, The Royal Society of Chemistry, Cambridge, 201440506-532;  DOI: 10.1039/9781849739986­‐00506

372. “A Carbohydrate-Based Julia-Kocienski Reagent for Syntheses of Chain-Extended and C-Linked Saccharides”
J. A. Bull, H. Kunz, Synthesis 201446DOI: 10.1055/s-0033-1340851.

371. “A Fully Synthetic Glycopeptide Antitumor Vaccine Based on Multiple Antigen Presentation on a Hyperbranched Polymer“
M. Glaffig, B. Palitzsch, S. Hartmann, C. Schüll, L. Nuhn, B. Gerlitzki, E. Schmitt, H. Frey, H.Kunz, Chem. Eur. J. 201415, 4232-4236; DOI: 10.1002/chem.201400256.

370. “Synthetic multivalent Glycopeptide-lipopeptide antitumor vaccine: Impact of the cluster effect on the killing of tumor cells”
Hui Cai, Zhan-Yi Sun, Mei-Sha Chen, Yu-Fen Zhao, Horst Kunz, Yan-Mei Li, Angew. Chem. 2014, 126, 1725-1729; Angew. Chem. Int. Ed. 2014, 53, 1699-1703; DOI: 10.1002/anie.201308875.

369. “Total synthesis of the antifungal natural product Mollisin“
S. Schwolow, H. Kunz, J. Rheinheimer, T. Opatz, Eur. J. Org. Chem. 2013, 29, 6519-6524; DOI: 10.1002/ejoc.201301088.

368. “Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines“
L. Nuhn, S. Hartmann, B. Palitzsch, B. Gerlitzki, E. Schmitt, R. Zentel, H. Kunz, Angew. Chem. 2013125, 10846-10850; Angew. Chem. Int. Ed. 2013, 52, 10652-10656; DOI: 10.1002/anie.201304212.

367. “Natural Product and Material Chemistries – Separated forever?“
H. Kunz und K. Müllen, J. Am. Chem. Soc. 2013, 135, 8764-8769; DOI: 10.1021/ja309186q.

366. “Fluorenylmethoxycarbonyl-N-methylamino acids synthesized in a flow tube-intube reactor with a liquid-liquid semipermeable membrane”
A. Buba, S. Koch, H. Kunz, H. Löwe, Eur. J. Org. Chem. 2013, 21, 4509-4513; DOI: 10.1002/ejoc.201300705.

365. "An anti-cancer jab? - Chemical synthesis of vaccines"
H. Kunz, S. Hartmann, B. Palitzsch, labor&more Special Edition 2013, 1.13, 28-33.
"Прививка от рака? - Химический синтез вакцин"
H. Kunz, S. Hartmann, B. Palitzsch, labor&more Special Edition Russia 2013, 2.13, 12-17.

364. "Self-Adjuvanting Synthetic Antitumor Vaccines from MUC1 Glycopeptides Conjugated to T-Cell Epitopes from Tetanus Toxoid”
Hui Cai, Mei-Sha Chen, Zhan-Yi Sun, Yu-Fen Zhao, Horst Kunz, Yan-Mei Li, Angew. Chem. 2013, 125, 6222-6226; Angew. Chem. Int. Ed. 2013, 52, 6106-6110. DOI: 10.1002/anie.201300390.

363. “C-Glycosyl Amino Acids via Hydroboration_Cross Coupling of exo-Glycals and their Application in Automated Solid-Phase Synthesis”
S. Koch, D. Schollmeyer, H. Löwe, H. Kunz, Chemistry Eur. J. 2013, 19, 7020-7041; DOI:10.1002/chem.201300150

362. “Fully Synthetic Self-Adjuvanting Thioether-Conjugated GlycopeptideLipopeptide Antitumor Vaccines for the Induction of Complement-Dependent Cytotoxicity against Tumor Cells”
H. Cai, Z.-Y. Sun, Z.-H. Huang, L. Shi, Y.-F. Zhao, H. Kunz, Y.-M. Li, Chemistry Eur. J. 2013, 19, 1962-1970.

361. "Impfung gegen Tumore? – Chemische Synthese von Vakzinen“
H. Kunz, S. Hartmann, B. Palitzsch, labor&more 2012 (6), 16-25.  zum Artikel

360. “The Development of Synthetic Antitumor Vaccines from Mucin Glycopeptide Antigens”
N. Gaidzik, U. Westerlind, H. Kunz, Chem. Soc. Rev. 2013, 42 (10), 4421–4442; DOI: 10.1039/C3CS35470A.

359."Stereoselective Synthesis of 3-Substituted and 3,4-Disubstituted Piperidines and Piperidin-2-one Derivatives“
E. Klegraf, H. Kunz, Z. Naturforsch. 2012, 67b, 389-405.

358. "Variation of the Glycosylation Pattern in MUC1 Glycopeptide BSA Vaccines and its Influence on the Immune Response"
Hui Cai, Zhi-Hua Huang, Lei Shi, Zhan-Yi Sun, Yu-Fen Zhao, H. Kunz, Yan-Mei Li, Angew. Chem. 2012, 124, 1751-1755; Angew. Chem. Int. Ed. 2012, 51, 1719-1724.

357. "Synthetische Antitumor-Vakzine aus MUC1-Glycopeptiden mit zwei immundominanten Domänen – Induktion einer starken Immunreaktion gegen Brusttumorgewebe"
N. Gaidzik, A. Kaiser, D. Kowalczyk, U. Westerlind, B. Gerlitzki, H. P. Sinn, E. Schmitt, H. Kunz, Angew. Chem. 2011, 123, 10153-7; Angew. Chem. Int. Ed. 2011, 50, 9977-9981.

356. "Petasis Olefination in a Continuous Flow Microwave Reactor: exo-Glycals from Sugar Lactones"
S. Koch, H. Löwe, H. Kunz, Synlett 2011, 1978-1982.

355. "Antitumor Vaccines Based on Synthetic Mucin Glycopeptides"
U. Westerlind, H. Kunz, in Anticarbohydrate Antibodies (Paul Kosma and Sven Müller-Loenies, Eds.), Springer Verlag, Wien, 2012, 255-281.

354. "Synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates and their Evaluation as Vaccines"
Hui Cai, Zhi-Hua Huang, Lei Shi, Peng Zou, Yu-Fen Zhao, H. Kunz, Yan-Mei Li, Eur. J. Org. Chem. 2011, 3685-3689.

353. "Towards a Fully Synthetic MUC1-Based Anticancer Vaccine: Efficient Conjugation of Glycopeptides with Mono-, Di- and Tetravalent Lipopeptides by Click Chemistry"
Hui Cai, Zhi-Hua Huang, Lei Shi, Yu-Fen Zhao, H. Kunz, Yan-Mei Li, Chemistry Eur. J. 2011, 17, 6396-6404.

352."Regioselective deacetylation and glycosylation in the synthesis of the sialy Lewis X tetrasaccharide, a key component of the recognition site of PSGL-1"
M. Pudelko, D. Kowalczyk, H. Kunz, Synlett 2010, 3023-3026.

351."Synthetic Vaccines from Tumor-Associated Glycopeptide Antigens"
U. Westerlind, H. Kunz, Chimia 2011, 65, 30-34.